Home
About
Overview
Sharing Data
ORCID
Help
History (18)
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Natalizumab induction and maintenance therapy for Crohn's disease.
Reviewing the Use of Vedolizumab for the Treatment of Patients With Crohn's Disease.
See All 18 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Reviewing the Use of Vedolizumab for the Treatment of Patients With Crohn's Disease.
Reviewing the Use of Vedolizumab for the Treatment of Patients With Crohn's Disease. Gastroenterol Hepatol (N Y). 2022 May; 18(5):287-290.
View in:
PubMed
authors with profiles
Stephen B. Hanauer